[Itraconazole in the treatment of ophthalmomycoses].

The method and results of the use of itrakonazol, a new antifungal agent of the imidazol class, in the treatment of fungal diseases of the eye are described. The clinical trials involved 50 patients with various clinical forms of ophthalmomycosis: 27 patients with fungal affection of the cornea, 3 patients with fungal endophthalmitis, 8 patients with fungal canaliculitis, 3 patients with fungal blepharitis and 9 patients with fungal conjunctivitis. The clinical trials showed that itraconazole had a sufficiently high antifungal activity in the treatment of the ophthalmomycoses. The drug is low toxic and well tolerated.
AuthorsIu F Maĭchuk, U V Diadina
JournalAntibiotiki i khimioterapii︠a︡ = Antibiotics and chemoterapy [sic] / Ministerstvo meditsinskoĭ i mikrobiologicheskoĭ promyshlennosti SSSR (Antibiot Khimioter) Vol. 39 Issue 7 Pg. 54-6 (Jul 1994) ISSN: 0235-2990 [Print] RUSSIA
Vernacular TitleItrakonazol v lechenii oftal'momikozov.
PMID7840712 (Publication Type: Clinical Trial, Controlled Clinical Trial, English Abstract, Journal Article)
Chemical References
  • Itraconazole
  • Blepharitis (drug therapy)
  • Conjunctivitis (drug therapy)
  • Corneal Diseases (drug therapy)
  • Endophthalmitis (drug therapy)
  • Eye Infections, Fungal (drug therapy)
  • Humans
  • Itraconazole (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: